立体定向体部放疗治疗局限性前列腺癌的回顾性分析
该回顾性研究分析了比利时安特卫普Iridium网络2020年1月1日至2022年12月31日接受SBRT的267例局限性前列腺癌患者,评估PACE-SBRT方案实施的急性和晚期泌尿生殖与胃肠道毒性及生化无复发生存。结果显示≥2级泌尿生殖毒性累积发生率为27%,胃肠道毒性为2%,2年生化无复发生存率为98.5%。
要点
- 267例患者中9%低危、51%中危、40%高危。
- ≥2级泌尿生殖毒性累积发生率27%,胃肠道毒性2%。
- 2年生化无复发生存率98.5%,生化复发4例(1.5%)。
核心结论
- SBRT治疗局限性前列腺癌肿瘤学结局良好,≥2级毒性发生率低。
- 研究结果与前赡性试验一致,提示SBRT是一种有效的治疗方式。
研究设计与样本
- 回顾性分析比利时安特卫普Iridium网络2020年1月1日至2022年12月31日接受SBRT的局限性前列腺癌患者267例。
- 急性毒性定义为SBRT后90天内发生的事件,晚期毒性在治疗后6个月、1年、2年和3年评估。
- 毒性和分级依据CTCAE 4.0版,生化复发依据Phoenix标准定义为PSA较治疗后最低值升高≥2 ng/mL。
主要发现
- 267例患者中9%为低危、51%为中危、40%为高危。
- ≥2级泌尿生殖毒性累积发生率为27%,≥2级胃肠道毒性累积发生率为2%。
- 24个月时11.5%(20/175)患者发生CTCAE≥2级泌尿生殖毒性,1.7%(3/175)发生≥2级胃肠道毒性。
- 生化复发发生于1.5%(4/267)患者,2年生化无复发生存率为98.5%。
临床怎么用
- 原文结论认为SBRT治疗局限性前列腺癌肿瘤学结局良好且≥2级毒性发生率低,结果与前赡性试验一致,提示SBRT是一种有效的治疗方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: External beam radiotherapy (EBRT) is a standard treatment for localized prostate cancer, with recent advancements favoring a reduced number of treatment sessions. Stereotactic body radiotherapy (SBRT) is a form of radiotherapy that delivers higher doses per fraction, typically in five or fewer sessions. This retrospective study aims to evaluate the implementation of the PACE-SBRT protocol for localized prostate cancer at our center by assessing the incidence and severity of toxicity, as well as biochemical relapse-free survival. METHODS: We conducted a retrospective analysis of patients with localized prostate cancer treated with SBRT at the Iridium Network in Antwerp, Belgium, who were treated between January 1, 2020, and December 31, 2022. Data were extracted from electronic medical records and included descriptive information on patient outcomes. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Acute toxicity was defined as events occurring within 90 days post-SBRT, whereas late toxicity was evaluated at 6 months, 1 year, 2 years, and 3 years post treatment. Biochemical recurrence was defined via the Phoenix criteria, as a rise in PSA levels of 2 ng/mL or more above the post treatment nadir. RESULTS: A total of 267 patients met the eligibility criteria for this study. In total, 9% of patients were low risk, 51% were intermediate risk, and 40% were high risk. The cumulative incidence of Grade 2 or higher GU toxicity was 27%, and for GI toxicity, it was 2%. At 24 months, 11.5% (20/175) of patients experienced CTCAE grade 2 or higher GU toxicity, and 1.7% (3/175) experienced grade 2 or higher GI toxicity. Biochemical relapse occurred in 1.5% (4/267) of patients, leading to a 2-year biochemical relapse-free survival rate of 98.5%. CONCLUSION: SBRT for localized prostate cancer has favorable oncological outcomes with a low incidence of Grade 2 or higher toxicity. The results of this study are consistent with findings from prospective trials, suggesting that SBRT is an effective treatment modality. Trial registration Retrospectively registered.
引用
- De Cooman B, Debacker T, Adams T, et al. Stereotactic body radiotherapy (SBRT) as a treatment for localized prostate cancer: a retrospective analysis. Radiat Oncol. 2025. PMID: 39985052. doi:10.1186/s13014-025-02598-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。